PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 1 filers reported holding PRELUDE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,754 | – | 23,198 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $57,226,239 | 1.12% |
| Baker Brothers Advisors | 10,123,824 | $57,705,797 | 0.31% |
| Boxer Capital, LLC | 699,047 | $3,985 | 0.20% |
| GSA CAPITAL PARTNERS LLP | 47,614 | $271 | 0.03% |
| DENALI ADVISORS LLC | 8,200 | $46,740 | 0.02% |
| 683 Capital Management, LLC | 28,631 | $163,197 | 0.01% |
| Virtu Financial LLC | 11,201 | $64 | 0.01% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 2,273,894 | $12,961,196 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $210,609 | 0.01% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 84,667 | $482,602 | 0.00% |